<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811016</url>
  </required_header>
  <id_info>
    <org_study_id>M2016</org_study_id>
    <nct_id>NCT02811016</nct_id>
  </id_info>
  <brief_title>Inhaled Budesonide and Acute Mountain Sickness</brief_title>
  <official_title>Effect of Inhaled Budesonide on the Incidence and Severity of Acute Mountain Sickness at 4559 m</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salzburger Landeskliniken</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Salzburger Landeskliniken</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate the effect of inhaled budesonide on the&#xD;
      incidence of AMS. The primary study question to ask is:&#xD;
&#xD;
      1. Does inhaled budesonide reduce the incidence of AMS after rapid and active ascent to 4559&#xD;
      m?&#xD;
&#xD;
      In addition, the secondary study questions to ask are:&#xD;
&#xD;
        1. Does inhaled budesonide reduce the severity of AMS after rapid and active ascent to 4559&#xD;
           m?&#xD;
&#xD;
        2. Are the effects of inhaled budesonide on AMS incidence and severity related to its&#xD;
           plasma concentration?&#xD;
&#xD;
      Study medication Inhaled budesonide at 2 different concentrations (2 x 200 µg, 2 x 800 µg)&#xD;
      versus placebo&#xD;
&#xD;
      Study design&#xD;
&#xD;
        -  Prospective, controlled, single-center study on 51 healthy volunteers at 4559 m [Capanna&#xD;
           Regina Margherita (Margherita Hut), Italy]&#xD;
&#xD;
        -  With regard to the intervention (inhaled budesonide) double-blinded and randomized&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective&#xD;
&#xD;
      The primary objective of the study is to investigate the effect of inhaled budesonide on the&#xD;
      incidence of AMS. The primary study question to ask is:&#xD;
&#xD;
      1. Does inhaled budesonide reduce the incidence of AMS after rapid and active ascent to 4559&#xD;
      m?&#xD;
&#xD;
      In addition, the secondary study questions to ask are:&#xD;
&#xD;
        1. Does inhaled budesonide reduce the severity of AMS after rapid and active ascent to 4559&#xD;
           m?&#xD;
&#xD;
        2. Are the effects of inhaled budesonide on AMS incidence and severity related to its&#xD;
           plasma concentration?&#xD;
&#xD;
      Study medication Inhaled budesonide at 2 different concentrations (2 x 200 µg, 2 x 800 µg)&#xD;
      versus placebo&#xD;
&#xD;
      Study design Prospective, controlled, single-center study on 51 healthy volunteers at 4559 m&#xD;
      [Capanna Regina Margherita (Margherita Hut), Italy] With regard to the intervention (inhaled&#xD;
      budensoide) double-blinded and randomized&#xD;
&#xD;
      Study population 51 healthy volunteers&#xD;
&#xD;
      Study site Prior to the study the pre-investigations will be performed at the University&#xD;
      Hospital Salzburg, Austria. The high-altitude part will take place at the Capanna Regina&#xD;
      Margherita (Margherita Hut, Italy) at 4559 m.&#xD;
&#xD;
      Interventions and investigations&#xD;
&#xD;
        -  Ascend from Alagna (1130 m, Italy) to the Margherita Hut (4559 m) in less than 24 h,&#xD;
           with a preceding overnight stay at 3611 m (Gnifetti Hut, Italy).&#xD;
&#xD;
        -  Stay at the Margherita Hut for 48 hours&#xD;
&#xD;
        -  Randomized inhalation of budesonide at two different concentrations (2 x 200 µg 2 x 800&#xD;
           µg, respectively) or placebo&#xD;
&#xD;
        -  Assessment of incidence and severity of acute mountain sickness by use of 2&#xD;
           internationally standardized and well established questionnaires&#xD;
&#xD;
        -  Venous (and capillary) blood drawings&#xD;
&#xD;
        -  Pulmonary function tests&#xD;
&#xD;
        -  Transthoracic echocardiography for assessing pulmonary artery systolic pressure&#xD;
&#xD;
      Number and volume of blood drawings For the study venous blood samples (volume: 20 ml each)&#xD;
      will be drawn at 5 different time points (5 x 20 ml = 100 ml). Together with the blood&#xD;
      drawing for the pre-investigation (20 ml) a total blood volume of 120 ml will be taken. At&#xD;
      the same time points capillary blood samples (1 ml) will be taken from the ear lobe for blood&#xD;
      gas analyses (5 x 1 ml = 5 ml in total).&#xD;
&#xD;
      Observational period The study will only start after approval by the ethic committee&#xD;
      responsible for the study (ethic committee of the Paracelsus Medical University). If the&#xD;
      study is approved it will be performed in July 2016.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute mountain sickness</measure>
    <time_frame>48 hrs at 4559 m</time_frame>
    <description>AMS scores positive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of acute mountain sickness</measure>
    <time_frame>48 hrs at 4559 m</time_frame>
    <description>Height of AMS scores</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Acute Mountain Sickness</condition>
  <arm_group>
    <arm_group_label>budesonide 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inhaled budesonide 200 µg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>budesonide 800</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inhaled budesonide 800 µg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>inhaled placebo bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 200</intervention_name>
    <description>200 µg inhaled at 7:00 a.m. and 7 p.m.</description>
    <arm_group_label>budesonide 200</arm_group_label>
    <other_name>Pulmicort Turbohaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 800</intervention_name>
    <description>800 µg inhaled at 7:00 a.m. and 7 p.m.</description>
    <arm_group_label>budesonide 800</arm_group_label>
    <other_name>Pulmicort Turbohaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Inhalation at 7:00 a.m. and 7 p.m.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Lactose-Monohydrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good physical condition&#xD;
&#xD;
          -  No relevant pathologies revealed by the pre-investigation prior to the study&#xD;
&#xD;
          -  Written informed consent to participate in the study&#xD;
&#xD;
          -  Permanent residency below 1000 m&#xD;
&#xD;
          -  Males and females are included without prioritization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute and chronic lung diseases&#xD;
&#xD;
          -  Conventional systolic blood pressure (average of two measurements) ≥150 mmHg and&#xD;
             conventional diastolic blood pressure ≥95 mmHg in untreated or treated subjects&#xD;
&#xD;
          -  Cardiovascular diseases other than hypertension (coronary heart disease, heart&#xD;
             failure, atrial fibrillation, peripheral artery disease)&#xD;
&#xD;
          -  Chronic headache / migraine&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Smoking (&gt;6 cigarettes/day) or equivalent nicotine substitutes&#xD;
&#xD;
          -  Alcohol (&gt;30 g/d) or drug abuse&#xD;
&#xD;
          -  Obesity (Body Mass Index &gt;30)&#xD;
&#xD;
          -  Other conditions deemed relevant by the investigator (including liver disease, renal&#xD;
             disease)&#xD;
&#xD;
          -  Sojourn &gt;2000 m within the last 4 weeks before the 1st study day&#xD;
&#xD;
          -  Drug intake within the last 2 moth before the 1st study day if the drug intake could&#xD;
             affect the data quality or the safety of the participants&#xD;
&#xD;
          -  Blood donation within the last 2 month before the 1st study day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc M Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, University Hospital Salzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology, University Hospital</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Salzburger Landeskliniken</investigator_affiliation>
    <investigator_full_name>Marc Berger</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>High Altitude</keyword>
  <keyword>budesonide</keyword>
  <keyword>hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

